QQQ   432.43 (+0.32%)
AAPL   169.67 (-1.75%)
MSFT   416.22 (+0.62%)
META   501.57 (+0.27%)
GOOGL   154.94 (+0.05%)
AMZN   183.81 (+0.10%)
TSLA   156.61 (-3.02%)
NVDA   877.45 (+2.03%)
AMD   163.57 (+2.03%)
NIO   3.85 (-1.03%)
BABA   69.98 (-0.91%)
T   16.06 (-1.11%)
F   12.19 (-0.33%)
MU   121.98 (+0.50%)
GE   156.80 (+2.02%)
CGC   6.80 (-2.58%)
DIS   114.02 (+0.95%)
AMC   2.77 (+12.15%)
PFE   25.79 (-0.46%)
PYPL   63.74 (+0.36%)
XOM   119.13 (-0.46%)
QQQ   432.43 (+0.32%)
AAPL   169.67 (-1.75%)
MSFT   416.22 (+0.62%)
META   501.57 (+0.27%)
GOOGL   154.94 (+0.05%)
AMZN   183.81 (+0.10%)
TSLA   156.61 (-3.02%)
NVDA   877.45 (+2.03%)
AMD   163.57 (+2.03%)
NIO   3.85 (-1.03%)
BABA   69.98 (-0.91%)
T   16.06 (-1.11%)
F   12.19 (-0.33%)
MU   121.98 (+0.50%)
GE   156.80 (+2.02%)
CGC   6.80 (-2.58%)
DIS   114.02 (+0.95%)
AMC   2.77 (+12.15%)
PFE   25.79 (-0.46%)
PYPL   63.74 (+0.36%)
XOM   119.13 (-0.46%)
QQQ   432.43 (+0.32%)
AAPL   169.67 (-1.75%)
MSFT   416.22 (+0.62%)
META   501.57 (+0.27%)
GOOGL   154.94 (+0.05%)
AMZN   183.81 (+0.10%)
TSLA   156.61 (-3.02%)
NVDA   877.45 (+2.03%)
AMD   163.57 (+2.03%)
NIO   3.85 (-1.03%)
BABA   69.98 (-0.91%)
T   16.06 (-1.11%)
F   12.19 (-0.33%)
MU   121.98 (+0.50%)
GE   156.80 (+2.02%)
CGC   6.80 (-2.58%)
DIS   114.02 (+0.95%)
AMC   2.77 (+12.15%)
PFE   25.79 (-0.46%)
PYPL   63.74 (+0.36%)
XOM   119.13 (-0.46%)
QQQ   432.43 (+0.32%)
AAPL   169.67 (-1.75%)
MSFT   416.22 (+0.62%)
META   501.57 (+0.27%)
GOOGL   154.94 (+0.05%)
AMZN   183.81 (+0.10%)
TSLA   156.61 (-3.02%)
NVDA   877.45 (+2.03%)
AMD   163.57 (+2.03%)
NIO   3.85 (-1.03%)
BABA   69.98 (-0.91%)
T   16.06 (-1.11%)
F   12.19 (-0.33%)
MU   121.98 (+0.50%)
GE   156.80 (+2.02%)
CGC   6.80 (-2.58%)
DIS   114.02 (+0.95%)
AMC   2.77 (+12.15%)
PFE   25.79 (-0.46%)
PYPL   63.74 (+0.36%)
XOM   119.13 (-0.46%)

Can B (CANB) Competitors

Notice: This company has been marked as potentially delisted and may not be actively trading.

CANB vs. NVTA, AKAN, VRAX, EVFM, CANOQ, CMRA, SPRC, NMTR, AMPE, and SDCCQ

Should you be buying Can B stock or one of its competitors? The main competitors of Can B include Invitae (NVTA), Akanda (AKAN), Virax Biolabs Group (VRAX), Evofem Biosciences (EVFM), Cano Health (CANOQ), Comera Life Sciences (CMRA), SciSparc (SPRC), 9 Meters Biopharma (NMTR), Ampio Pharmaceuticals (AMPE), and SmileDirectClub (SDCCQ). These companies are all part of the "medical" sector.

Can B vs.

Invitae (NYSE:NVTA) and Can B (NASDAQ:CANB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, community ranking, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation.

Invitae has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500. Comparatively, Can B has a beta of 2.8, indicating that its stock price is 180% more volatile than the S&P 500.

In the previous week, Can B had 42 more articles in the media than Invitae. MarketBeat recorded 45 mentions for Can B and 3 mentions for Invitae. Invitae's average media sentiment score of -0.14 beat Can B's score of -0.51 indicating that Can B is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Invitae
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Negative
Can B
2 Very Positive mention(s)
11 Positive mention(s)
18 Neutral mention(s)
11 Negative mention(s)
3 Very Negative mention(s)
Neutral

Invitae received 434 more outperform votes than Can B when rated by MarketBeat users. Likewise, 61.03% of users gave Invitae an outperform vote while only 58.62% of users gave Can B an outperform vote.

CompanyUnderperformOutperform
InvitaeOutperform Votes
451
61.03%
Underperform Votes
288
38.97%
Can BOutperform Votes
17
58.62%
Underperform Votes
12
41.38%

61.3% of Invitae shares are held by institutional investors. Comparatively, 6.1% of Can B shares are held by institutional investors. 0.7% of Invitae shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Invitae has a net margin of -299.14% compared to Invitae's net margin of -442.95%. Invitae's return on equity of 0.00% beat Can B's return on equity.

Company Net Margins Return on Equity Return on Assets
Invitae-299.14% -6,100.71% -19.68%
Can B -442.95%N/A -73.68%

Invitae currently has a consensus target price of $1.00, suggesting a potential upside of 124,900.00%. Given Can B's higher possible upside, equities analysts plainly believe Invitae is more favorable than Can B.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Invitae
3 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Can B
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Can B has lower revenue, but higher earnings than Invitae. Can B is trading at a lower price-to-earnings ratio than Invitae, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Invitae$481.58M0.00-$3.11B-$5.380.00
Can B$6.69M0.17-$14.92M-$1.71-0.02

Summary

Invitae beats Can B on 9 of the 16 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CANB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CANB vs. The Competition

MetricCan BDrugs, proprietaries, & sundries IndustryMedical SectorNASDAQ Exchange
Market Cap$1.16M$15.30B$4.73B$7.50B
Dividend YieldN/A1.26%5.47%3.96%
P/E Ratio-0.0235.18206.2515.63
Price / Sales0.172.432,530.7487.79
Price / CashN/A9.8233.3728.19
Price / Book-0.0213.464.664.27
Net Income-$14.92M$665.71M$100.20M$210.80M

Can B Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NVTA
Invitae
1.8187 of 5 stars
N/A$1.00
+∞
-99.3%$1.07M$481.58M0.001,700Analyst Report
News Coverage
Gap Down
AKAN
Akanda
0 of 5 stars
$0.12
flat
N/A-89.6%$1.07M$3.94M0.0046Gap Down
VRAX
Virax Biolabs Group
0 of 5 stars
$0.77
-3.8%
N/A-89.1%$1.20M$79,301.000.0011News Coverage
EVFM
Evofem Biosciences
0 of 5 stars
$0.02
flat
N/A-99.5%$1.05M$11.39M0.0035Gap Up
CANOQ
Cano Health
0 of 5 stars
$0.23
-4.3%
N/AN/A$1.22M$3.14B0.002,700Gap Down
CMRA
Comera Life Sciences
0 of 5 stars
$0.03
-22.7%
N/A-92.7%$1.05M$1.00M-0.0712Gap Down
SPRC
SciSparc
0 of 5 stars
$1.73
-3.9%
N/A-87.8%$1.22M$2.88M0.003Short Interest ↑
NMTR
9 Meters Biopharma
0 of 5 stars
N/A$1.70
+∞
N/A$1.04MN/A-0.0210
AMPE
Ampio Pharmaceuticals
0 of 5 stars
$0.88
-1.1%
N/A-92.6%$1.01MN/A-0.085Analyst Report
SDCCQ
SmileDirectClub
0 of 5 stars
$0.00
flat
N/AN/A$1.01M$470.74M0.002,700News Coverage

Related Companies and Tools

This page (NASDAQ:CANB) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners